Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.7% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price fell 5.7% on Tuesday . The company traded as low as $35.01 and last traded at $34.99. 10,073 shares were traded during mid-day trading, a decline of 83% from the average session volume of 60,093 shares. The stock had previously closed at $37.12.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NBTX. UBS Group boosted their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Guggenheim boosted their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Leerink Partners boosted their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. Finally, TD Cowen reissued a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Nanobiotix currently has an average rating of “Moderate Buy” and a consensus price target of $37.33.

Nanobiotix Price Performance

The firm’s 50 day moving average price is $37.75 and its two-hundred day moving average price is $29.57.

Nanobiotix (NASDAQ:NBTX) last posted its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million for the quarter. As a group, equities research analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.19 EPS for the current fiscal year.

Institutional Trading of Nanobiotix

A number of institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its holdings in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Optiver Holding B.V. purchased a new stake in Nanobiotix during the 3rd quarter worth about $101,000. Marshall Wace LLP purchased a new stake in Nanobiotix during the 4th quarter worth about $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix during the 4th quarter worth about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.